Endothelin antagonism as an active principle for glaucoma therapy

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 806-816

  Rosenthal, Rita ^a   Fromm, Michael ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

endothelin; endothelin receptor blocker; glaucoma; intraocular pressure; ocular blood flow; prostaglandin analogues; retinal ganglion cells; trabecular meshwork

Indexed keywords

AMBRISENTAN; BIMATOPROST; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; LATANOPROST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER; TAFLUPROST; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

BIRTH DEFECT; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TARGETING; EYE BLOOD FLOW; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LIVER TOXICITY; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RETINA GANGLION CELL; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; TRABECULAR MESHWORK;

ANIMALS; ENDOTHELINS; EYE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MOLECULAR TARGETED THERAPY; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; RETINAL GANGLION CELLS;

EID: 79251478081     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01103.x     Document Type: Review

References (117)

1. Alagoz G, Gurel K, Bayer A, Serin D, Celebi S, Kukner S, (2008). A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 222: 88-95.
2. Al-Jazzaf AM, DeSantis L, Netland PA, (2003). Travoprost: a potent ocular hypotensive agent. Drugs Today 39: 61-74.
3. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH, (2008). Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 145: 114-119.
4. Benigni A, Remuzzi G, (1999). Endothelin antagonists. Lancet 353: 133-138.
5. Benigni A, Perico N, Remuzzi G, (2004). The potential of endothelin antagonism as a therapeutic approach. Expert Opin Investig Drugs 13: 1419-1435.
6. Chauhan BC, LeVatte TL, Jollimore CA, Yu PK, Reitsamer HA, Kelly ME, et al. (2004). Model of endothelin-1-induced chronic optic neuropathy in rat. Invest Ophthalmol Vis Sci 45: 144-152.
7. Choritz L, Rosenthal R, Fromm M, Foerster MH, Thieme H, (2005). Pharmacological and functional characterization of endothelin receptors in bovine trabecular meshwork and ciliary muscle. Ophthalmic Res 37: 179-187.
8. Cioffi GA, Sullivan P, (1999). The effect of chronic ischemia on the primate optic nerve. Eur J Ophthalmol 9: S34-S36.
9. Cioffi GA, Orgul S, Onda E, Bacon DR, Van Buskirk EM, (1995). An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. Curr Eye Res 14: 1147-1153.
10. Clozel M, Gray GA, (1995). Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 26: 262-264.
11. Dallinger S, Dorner GT, Wenzel R, Graselli U, Findl O, Eichler HG, et al. (2000). Endothelin-1 contributes to hyperoxia-induced vasoconstriction in the human retina. Invest Ophthalmol Vis Sci 41: 864-869.
12. Davenport AP, (2002). International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226.
13. Desai D, He S, Yorio T, Krishnamoorthy RR, Prasanna G, (2004). Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. Biochem Biophys Res Commun 318: 642-648.
14. Dibas A, Prasanna G, Yorio T, (2005a). Characterization of endothelin-converting enzyme activities in ARPE-19 cells, a human retinal pigmented epithelial cell line. J Ocul Pharmacol Ther 21: 196-204.
15. Dibas A, Prasanna G, Yorio T, (2005b). Localization of endothelin-converting enzyme in bovine optic nerve and retina. J Ocul Pharmacol Ther 21: 288-297.
16. Emre M, Orgul S, Haufschild T, Shaw SG, Flammer J, (2005). Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol 89: 60-63.
17. Erickson-Lamy K, Korbmacher C, Schuman JS, Nathanson JA, (1991). Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo. Invest Ophthalmol Vis Sci 32: 492-495.
18. Erkin EF, Tarhan S, Kayikcioglu OR, Deveci H, Guler C, Goktan C, (2004). Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol 14: 211-219.
19. Fernandez-Durango R, Rollin R, Mediero A, Roldan-Pallares M, Garcia Feijo J, Garcia Sanchez J, et al. (2003). Localization of endothelin-1 mRNA expression and immunoreactivity in the anterior segment of human eye: expression of ETA and ETB receptors. Mol Vis 9: 103-109.
20. Flammer J, Mozaffarieh M, (2008). Autoregulation, a balancing act between supply and demand. Can J Ophthalmol 43: 317-321.
21. Flammer J, Haefliger IO, Orgul S, Resink T, (1999). Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma 8: 212-219.
22. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. (2002). The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 21: 359-393.
23. Fuchsjager-Mayrl G, Luksch A, Malec M, Polska E, Wolzt M, Schmetterer L, (2003). Role of endothelin-1 in choroidal blood flow regulation during isometric exercise in healthy humans. Invest Ophthalmol Vis Sci 44: 728-733.
24. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN, (2001). Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 119: 1165-1170.
25. Georgopoulos GT, Diestelhorst M, Fisher R, Ruokonen P, Krieglstein GK, (2002). The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow. Acta Ophthalmol Scand 80: 54-58.
26. Gherghel D, Hosking SL, Cunliffe IA, Armstrong RA, (2008). First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study. Eye (Lond) 22: 363-369.
27. Granstam E, Wang L, Bill A, (1991). Effects of endothelins (ET-1, ET-2 and ET-3) in the rabbit eye; role of prostaglandins. Eur J Pharmacol 194: 217-223.
28. Granstam E, Wang L, Bill A, (1992). Ocular effects of endothelin-1 in the cat. Curr Eye Res 11: 325-332.
29. Haefliger IO, Flammer J, Luscher TF, (1993). Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. Invest Ophthalmol Vis Sci 34: 1722-1730.
30. Haque MS, Sugiyama K, Taniguchi T, Kitazawa Y, (1996). Effects of BQ-123, an ETA recepter-selective antagonist, on changes of intraocular pressure, blood-aqueous barrier and aqueous prostaglandin concentrations caused by endothelin-1 in rabbit. Jpn J Ophthalmol 40: 26-32.
31. Henry E, Newby DE, Webb DJ, Hadoke PW, O'Brien CJ, (2006). Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. Invest Ophthalmol Vis Sci 47: 2528-2532.
32. Hernandez MR, (2000). The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res 19: 297-321.
33. Hollo G, Lakatos P, Farkas K, (1998). Cold pressor test and plasma endothelin-1 concentration in primary open-angle and capsular glaucoma. J Glaucoma 7: 105-110.
34. Hollo G, Lakatos P, Vargha P, (2000). Immediate increase in aqueous humour endothelin 1 concentration and intra-ocular pressure after argon laser trabeculoplasty in the rabbit. Ophthalmologica 214: 292-295.
35. Hollo G, Kothy P, Lakatos P, Vargha P, (2002). Endothelin-A receptor antagonist BQ-485 protects against intraocular pressure spike induced by laser trabeculoplasty in the rabbit. Ophthalmologica 216: 459-462.
36. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, et al. (2001). Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 42: 137-144.
37. Honjo M, Inatani M, Kido N, Sawamura T, Yue BY, Honda Y, et al. (2002). A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res 75: 135-142.
38. Hylton C, Robin AL, (2003). Update on prostaglandin analogs. Curr Opin Ophthalmol 14: 65-69.
39. Kallberg ME, Brooks DE, Garcia-Sanchez GA, Komaromy AM, Szabo NJ, Tian L, (2002). Endothelin 1 levels in the aqueous humor of dogs with glaucoma. J Glaucoma 11: 105-109.
40. Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A, (2009). Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol 247: 1353-1360.
41. Karadag R, Yagci R, Aydin B, Kanbay M, Erdurmus M, Keskin UC, et al. (2009). Effects of erytropoietin treatment and hemodialysis on the serum endothelin level and intraocular pressure of hemodialysis patients. Int Ophthalmol 29: 385-388.
42. Kim JW, Lindsey JD, Wang N, Weinreb RN, (2001). Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42: 1514-1521.
43. Kingman M, Ruggiero R, Torres F, (2009). Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 10: 1847-1858.
44. Koliakos GG, Konstas AG, Schlotzer-Schrehardt U, Hollo G, Mitova D, Kovatchev D, et al. (2004). Endothelin-1 concentration is increased in the aqueous humour of patients with exfoliation syndrome. Br J Ophthalmol 88: 523-527.
45. Konno T, Maruichi M, Takai S, Oku H, Sugiyama T, Uchibori T, et al. (2005). Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol 524: 132-137.
46. Krishnamoorthy RR, Rao VR, Dauphin R, Prasanna G, Johnson C, Yorio T, (2008). Role of the ETB receptor in retinal ganglion cell death in glaucoma. Can J Physiol Pharmacol 86: 380-393.
47. Kudo H, Nakazawa T, Shimura M, Takahashi H, Fuse N, Kashiwagi K, et al. (2006). Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol 244: 1003-1009.
48. Kunimatsu S, Mayama C, Tomidokoro A, Araie M, (2006). Plasma endothelin-1 level in Japanese normal tension glaucoma patients. Curr Eye Res 31: 727-731.
49. Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T, (2010). Effects of prostaglandin F2a analogues on endothelin-1-induced impairmentof rabbit ocular blood fl ow: comparison among ta fl uprost, travoprost,and latanoprost. Exp Eye Res DOI:10.1016/j.exer.2010.09.004.
50. Lepple-Wienhues A, Becker M, Stahl F, Berweck S, Hensen J, Noske W, et al. (1992). Endothelin-like immunoreactivity in the aqueous humour and in conditioned medium from cultured ciliary epithelial cells. Curr Eye Res 11: 1041-1046.
51. Levin ER, (1995). Endothelins. N Engl J Med 333: 356-363.
52. Lu YB, Franze K, Seifert G, Steinhauser C, Kirchhoff F, Wolburg H, et al. (2006). Viscoelastic properties of individual glial cells and neurons in the CNS. Proc Natl Acad Sci U S A 103: 17759-17764.
53. Lüscher TF, Wenzel RR, (1995). Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions Suppl 45: 237-253.
54. MacCumber MW, D'Anna SA, (1994). Endothelin receptor-binding subtypes in the human retina and choroid. Arch Ophthalmol 112: 1231-1235.
55. MacCumber MW, Jampel HD, Snyder SH, (1991). Ocular effects of the endothelins. Abundant peptides in the eye. Arch Ophthalmol 109: 705-709.
56. McKibbin M, Menage MJ, (1999). The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye (Lond) 13: 31-34.
57. Mukuno H, Nakamura M, Kanamori A, Nagai A, Negi A, Seigel G, (2004). Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Curr Eye Res 29: 457-464.
58. Munemasa Y, Kitaoka Y, Hayashi Y, Takeda H, Fujino H, Ohtani-Kaneko R, et al. (2008). Effects of unoprostone on phosphorylated extracellular signal-regulated kinase expression in endothelin-1-induced retinal and optic nerve damage. Vis Neurosci 25: 197-208.
59. Nakanishi Y, Nakamura M, Mukuno H, Kanamori A, Seigel GM, Negi A, (2006). Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp Eye Res 83: 1108-1117.
60. Narayan S, Prasanna G, Krishnamoorthy RR, Zhang X, Yorio T, (2003). Endothelin-1 synthesis and secretion in human retinal pigment epithelial cells (ARPE-19): differential regulation by cholinergics and TNF-alpha. Invest Ophthalmol Vis Sci 44: 4885-4894.
61. Narayan S, Brun AM, Yorio T, (2004). Endothelin-1 distribution and basolateral secretion in the retinal pigment epithelium. Exp Eye Res 79: 11-19.
62. Nguyen QH, (2004). The role of prostaglandin analogues in the treatment of glaucoma in the 21st century. Int Ophthalmol Clin 44: 15-27.
63. Nilsson SF, (1997). The uveoscleral outflow routes. Eye 11: 149-154.
64. Noske W, Hensen J, Wiederholt M, (1997). Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch Clin Exp Ophthalmol 235: 551-552.
65. Okada K, Sugiyama K, Haque MS, Taniguchi T, Kitazawa Y, (1995). The effects of endothelin-1 on intraocular pressure and pupillary diameter in rabbits. Jpn J Ophthalmol 39: 233-241.
66. Oku H, Sugiyama T, Kojima S, Watanabe T, Azuma I, (1999). Experimental optic cup enlargement caused by endothelin-1-induced chronic optic nerve head ischemia. Surv Ophthalmol 44: S74-S84.
67. Orgul S, Cioffi GA, Bacon DR, Van Buskirk EM, (1996a). An endothelin-1-induced model of chronic optic nerve ischemia in rhesus monkeys. J Glaucoma 5: 135-138.
68. Orgul S, Cioffi GA, Wilson DJ, Bacon DR, Van Buskirk EM, (1996b). An endothelin-1 induced model of optic nerve ischemia in the rabbit. Invest Ophthalmol Vis Sci 37: 1860-1869.
69. Orgul S, Zawinka C, Gugleta K, Flammer J, (2005). Therapeutic strategies for normal-tension glaucoma. Ophthalmologica 219: 317-323.
70. Ota T, Aihara M, Narumiya S, Araie M, (2005). The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 46: 4159-4163.
71. Pache M, Kaiser HJ, Akhalbedashvili N, Lienert C, Dubler B, Kappos L, et al. (2003). Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. Eur Neurol 49: 164-168.
72. Perry CM, McGavin JK, Culy CR, Ibbotson T, (2003). Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 20: 597-630.
73. Pinet F, (2004). What is the role of endothelin system? Med Sci (Paris) 20: 339-345.
74. Polak K, Petternel V, Luksch A, Krohn J, Findl O, Polska E, et al. (2001). Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci 42: 2949-2956.
75. Polak K, Luksch A, Frank B, Jandrasits K, Polska E, Schmetterer L, (2003). Regulation of human retinal blood flow by endothelin-1. Exp Eye Res 76: 633-640.
76. Polska E, Doelemeyer A, Luksch A, Ehrlich P, Kaehler N, Percicot CL, et al. (2002). Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol 120: 348-352.
77. Prasanna G, Dibas A, Tao W, White K, Yorio T, (1998). Regulation of endothelin-1 in human non-pigmented ciliary epithelial cells by tumor necrosis factor-alpha. Exp Eye Res 66: 9-18.
78. Prasanna G, Dibas A, Finkley A, Yorio T, (1999). Identification of endothelin converting enzyme-1 in human non-pigmented ciliary epithelial cells. Exp Eye Res 69: 175-183.
79. Prasanna G, Krishnamoorthy R, Clark AF, Wordinger RJ, Yorio T, (2002). Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci 43: 2704-2713.
80. Prasanna G, Narayan S, Krishnamoorthy RR, Yorio T, (2003). Eyeing endothelins: a cellular perspective. Mol Cell Biochem 253: 71-88.
81. Prasanna G, Hulet C, Desai D, Krishnamoorthy RR, Narayan S, Brun AM, et al. (2005). Effect of elevated intraocular pressure on endothelin-1 in a rat model of glaucoma. Pharmacol Res 51: 41-50.
82. Rao PV, Deng PF, Kumar J, Epstein DL, (2001). Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42: 1029-1037.
83. Renieri G, Choritz L, Rosenthal R, Meissner S, Pfeiffer N, Thieme H, (2008). Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork. Graefes Arch Clin Exp Ophthalmol 246: 1107-1115.
84. Resch H, Karl K, Weigert G, Wolzt M, Hommer A, Schmetterer L, et al. (2009). Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects. Invest Ophthalmol Vis Sci 50: 358-363.
85. Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, et al. (2005). Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res 80: 837-845.
86. Rosenthal R, Choritz L, Zorn R, Münzer G, Fromm M, Pfeiffer N, et al. (2007). Endothelin receptor B in trabecular meshwork. Exp Eye Res 85: 482-491.
87. Rubin LJ, Roux S, (2002). Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 11: 991-1002.
88. Sponsel WE, Paris G, Trigo Y, Pena M, (2002a). Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol 134: 552-559.
89. Sponsel WE, Paris G, Trigo Y, Pena M, Weber A, Sanford K, et al. (2002b). Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol 133: 11-18.
90. Stitt AW, Chakravarthy U, Gardiner TA, Archer DB, (1996). Endothelin-like immunoreactivity and receptor binding in the choroid and retina. Curr Eye Res 15: 111-117.
91. Stokely ME, Brady ST, Yorio T, (2002). Effects of endothelin-1 on components of anterograde axonal transport in optic nerve. Invest Ophthalmol Vis Sci 43: 3223-3230.
92. Sugiyama T, Azuma I, (1995). Effect of UF-021 on optic nerve head circulation in rabbits. Jpn J Ophthalmol 39: 124-129.
93. Sugiyama K, Haque MS, Okada K, Taniguchi T, Kitazawa Y, (1995a). Intraocular pressure response to intravitreal injection of endothelin-1 and the mediatory role of ETA receptor, ETB receptor, and cyclooxygenase products in rabbits. Curr Eye Res 14: 479-486.
94. Sugiyama T, Moriya S, Oku H, Azuma I, (1995b). Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol 39: 49-56.
95. Sugiyama T, Utsumi T, Azuma I, Fujii H, (1996). Measurement of optic nerve head circulation: comparison of laser speckle and hydrogen clearance methods. Jpn J Ophthalmol 40: 339-343.
96. Sugiyama T, Mashima Y, Yoshioka Y, Oku H, Ikeda T, (2009). Effect of unoprostone on topographic and blood flow changes in the ischemic optic nerve head of rabbits. Arch Ophthalmol 127: 454-459.
97. Taniguchi T, Okada K, Haque MS, Sugiyama K, Kitazawa Y, (1994). Effects of endothelin-1 on intraocular pressure and aqueous humor dynamics in the rabbit eye. Curr Eye Res 13: 461-464.
98. Taniguchi T, Haque MS, Sugiyama K, Okada K, Nakai Y, Kitazawa Y, (1996). Effects of endothelin A and B receptors on aqueous humor dynamics in the rabbit eye. J Ocul Pharmacol Ther 12: 123-130.
99. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB, (1997). Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma 6: 83-89.
100. Thieme H, Stumpff F, Ottlecz A, Percicot CL, Lambrou GN, Wiederholt M, (2001). Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 42: 3193-3201.
101. Thieme H, Schimmat C, Münzer G, Boxberger M, Fromm M, Pfeiffer N, et al. (2006). Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 47: 938-945.
102. Tian B, Brumback LC, Kaufman PL, (2000). ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey eye. Exp Eye Res 71: 551-566.
103. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. (2007). Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 48: 3216-3222.
104. Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, et al. (2007). Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 16: 189-195.
105. Vetrugno M, Cantatore F, Gigante G, Cardia L, (1998). Latanoprost 0.005% in POAG: effects on IOP and ocular blood flow. Acta Ophthalmol Scand Suppl 227: 40-41.
106. Vidal L, Diaz F, Villena A, Moreno M, Campos JG, Perez de Vargas I, (2010). Reaction of Muller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res Bull 82: 18-24.
107. Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, et al. (2007). Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 48: 4107-4115.
108. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD, (1997). Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38: 2772-2780.
109. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL, (2002). Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 47: 53-64.
110. Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A, (2004). Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci 45: 4368-4377.
111. Wiederholt M, Bielka S, Schweig F, Lütjen-Drecoll E, Lepple-Wienhues A, (1995). Regulation of outflow rate and resistance in the perfused anterior segment of the bovine eye. Exp Eye Res 61: 223-234.
112. Wiederholt M, Thieme H, Stumpff F, (2000). The regulation of trabecular meshwork and ciliary muscle contractility. Prog Ret Eye Res 19: 271-295.
113. Wollensak G, Schaefer HE, Ihling C, (1998). An immunohistochemical study of endothelin-1 in the human eye. Curr Eye Res 17: 541-545.
114. Wollensak G, Löffler B, Beyermann B, Ihling C, (2002). An immunohistochemical study of endothelin-1 converting enzyme in the human eye. Curr Eye Res 24: 6-11.
115. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.
116. Yorio T, Krishnamoorthy R, Prasanna G, (2002). Endothelin: is it a contributor to glaucoma pathophysiology? J Glaucoma 11: 259-270.
117. Yu DY, Su EN, Cringle SJ, Schoch C, Percicot CP, Lambrou GN, (2001). Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci 42: 1499-1504.